Bioventix (BVXP)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

3,950.00p
   
  • Change Today:
      50.00p
  • 52 Week High: 4,500.00p
  • 52 Week Low: 3,800.00p
  • Currency: UK Pounds
  • Shares Issued: 5.21m
  • Volume: 8,977
  • Market Cap: £205.77m

Bioventix profits shoot higher on vit-D tests, but may plateau

By Iain Gilbert

Date: Monday 16 Oct 2017

LONDON (ShareCast) - (ShareCast News) - Biotech group Bioventix lifted annual pre-tax profits by more than a third as revenue was boosted by a significant increase in sales of its vitamin D antibody.
Bioventix announced annual revenue of £7.2m, up from £5.5m a year earlier, and PBT up 37% to £5.7m as part of a strong set of results on Monday, also helped by keeping cost increases to a minimum.

The firm increased its cash balance to £6.1m from £5.3m.

Bioventix collected £2.75m from sales of vitD3.5H10, its vitamin D antibody, a 24% improvement on the 2016 financial year which surpassed management's expectations.

However, the group warned that its "prudent belief" was that the vitamin D market would plateau in the near future, and may only record a "modest further increase" in the coming fiscal period.

Basic earnings per share shot up to 96.3p from 69.18p a year earlier.

As of 0940 BST, shares had backtracked 1.45% to 2,275.00p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

Bioventix Market Data

Currency UK Pounds
Share Price 3,950.00p
Change Today 50.00p
% Change 1.28 %
52 Week High 4,500.00p
52 Week Low 3,800.00p
Volume 8,977
Shares Issued 5.21m
Market Cap £205.77m

Bioventix Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
84.37% below the market average84.37% below the market average84.37% below the market average84.37% below the market average84.37% below the market average
72.55% below the sector average72.55% below the sector average72.55% below the sector average72.55% below the sector average72.55% below the sector average
Price Trend
63.04% below the market average63.04% below the market average63.04% below the market average63.04% below the market average63.04% below the market average
47.54% below the sector average47.54% below the sector average47.54% below the sector average47.54% below the sector average47.54% below the sector average
Income Not Available
Growth
78.01% above the market average78.01% above the market average78.01% above the market average78.01% above the market average78.01% above the market average
2.86% above the sector average2.86% above the sector average2.86% above the sector average2.86% above the sector average2.86% above the sector average

Bioventix Dividends

  Latest Previous
  1st Interim Special
Ex-Div 08-Apr-21 29-Oct-20
Paid 23-Apr-21 13-Nov-20
Amount 43.00p 53.00p

Trades for 05-Aug-2021

Time Volume / Share Price
11:42 3,000 @ 3,851.00p
11:42 3,000 @ 3,850.00p
15:39 1,250 @ 3,880.00p
16:13 99 @ 3,925.00p
16:06 50 @ 3,920.00p

Bioventix Key Personnel

CEO Peter John Harrison
Chair Ian James Nicholson
CFO Bruce Hiscock

Top of Page